On Nov 27, major Wall Street analysts update their ratings for $Alector (ALEC.US)$, with price targets ranging from $3 to $7.
Morgan Stanley analyst Jeffrey Hung downgrades to a sell rating, and adjusts the target price from $10 to $3.
TD Cowen analyst Yaron Werber maintains with a buy rating.
Mizuho Securities analyst Graig Suvannavejh maintains with a buy rating.
H.C. Wainwright analyst Andrew Fein maintains with a buy rating, and adjusts the target price from $35 to $7.
Furthermore, according to the comprehensive report, the opinions of $Alector (ALEC.US)$'s main analysts recently are as follows:
Following the Phase 2 INVOKE-2 study results indicating that AL002 did not decelerate Alzheimer's progression nor affect disease biomarkers, there's a tempered perspective on this drug's immediate potential. Nonetheless, optimism remains for the potential of latozinemab, though the focus may shift more favorably towards other opportunities within the analyst's coverage, pending further data expected from the Phase 3 INFRONT-3 trials in frontotemporal dementia projected around late 2025 or early 2026.
The activation of TREM2 showed limited efficacy in Alzheimer's disease, representing a challenge for the domain of genome-wide association studies-driven medicine. Additionally, the mechanism of ARIA-E may need further evaluation.
Here are the latest investment ratings and price targets for $Alector (ALEC.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
